A case of pembrolizumab-induced severe DKA and hypothyroidism in a patient with metastatic melanoma

Immune checkpoint inhibitors (ICIs) have revolutionised cancer therapy and improved outcomes for patients with advanced disease. Pembrolizumab, a monoclonal antibody that acts as a programmed cell death 1 (PD-1(PDCD1)) inhibitor, has been approved for the treatment of advanced melanoma and other sol...

Descripción completa

Detalles Bibliográficos
Autores principales: Hakami, Osamah A, Ioana, Julia, Ahmad, Shahzad, Tun, Tommy Kyaw, Sreenan, Seamus, McDermott, John H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2019
Materias:
Unusual Effects of Medical Treatment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6432978/
https://www.ncbi.nlm.nih.gov/pubmed/30836329
http://dx.doi.org/10.1530/EDM-18-0153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6432978/
https://www.ncbi.nlm.nih.gov/pubmed/30836329
http://dx.doi.org/10.1530/EDM-18-0153

Ejemplares similares